Michael E. Thase, MD
Dr. Thase is an expert in assessment and treatment of mood disorders, with particular interest in major depressive disorders, long-term treatment and combination therapy. His current PI work includes a study of cognitive therapy for depression treatment, a multi-site investigation of psychotherapy and medication in addressing major depression, and a placebo-controlled, randomized clinical trial on the use of continuation-phase cognitive therapy and fluoxetine for major depressive disorder. In addition, Dr. Thase is editor-in-chief of Psychopharmacology Bulletin.
- Professor of Psychiatry, University of Pittsburgh Medical Center; Western Psychiatric Institute and Clinic
- MD, 1979, Ohio State University
- Thase ME. Preventing relapse and recurrence of depression: A brief review of therapeutic options. CNS Spectrums. 2006;11(Suppl 15):12-21.
- Thase ME. New directions in the treatment of atypical depression. J Clin Psychiatry. 2006;67.
- Thase ME. The failure of evidence-based medicine to guide treatment of antidepressant nonresponders. J Clin Psychiatry. 2006;67:1833-1835.
- Thase ME. Treatment-resistant depression and the bipolar spectrum: Recognition and management. Primary Psychiatry. 2006;13:59-67.
- Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between Bupropion XL and Venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006;26:482-488.
- Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (The BOLDER II Study). J Clin Psychopharmacol. 2006;26: 600-609.
- Becoming an Effective Employer
- Co-PI Relationships
- Funding Large Studies
- Have Your Eyes Open
- Staying in Touch with the Project
- The Bigger Picture
- Two Career Diversions
- University Peer Review